New study digs into long-term survival data for advanced lung cancer patients on immunotherapy
NCT ID NCT07478809
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks back at patients with advanced squamous non-small cell lung cancer who received tislelizumab combined with chemotherapy in a previous trial. Researchers want to see how long patients lived and find out who benefits most from this treatment. The goal is to better understand the long-term effects of immunotherapy in this type of lung cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab (an immunotherapy drug) combined with chemotherapy
What this could lead to
If successful, this could help doctors identify which patients with advanced squamous NSCLC are most likely to benefit from long-term immunotherapy treatment.
What could go wrong
This is a retrospective analysis of a previous trial, not a new treatment test. Results may not apply to all patients, and long-term data may still be limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••